Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Medicina (Kaunas) ; 58(3)2022 Feb 25.
Article in English | MEDLINE | ID: covidwho-1765784

ABSTRACT

Background and Objectives: The aim of this study was to evaluate short-term continuous positive air pressure (CPAP) treatment for health-related quality of life (HRQL) in patients with obstructive sleep apnea. Materials and Methods: Our subjects were 18-65 years old, diagnosed with moderate-to-severe obstructive sleep apnea and treated with CPAP between January 2020 and June 2021 in Hospital of Lithuanian University of Health Sciences Kaunas clinics. All the patients completed the Epworth Sleepiness Scale (ESS), the 36-Item Short Form Health Survey (SF-36), the and Pittsburgh Sleep Quality Index (PSQI) before and after 3 months of treatment. Polysomnography was also repeated. Statistical analyses were performed using SPSS 27.0 software. The value of p < 0.05 was considered as statistically significant. Results: The active-treatment group comprised 17 subjects with a mean age of 51.9 ± 8.9 years. The total SF-36 questionnaire score improved from 499.8 ± 122.3 to 589.6 ± 124.7 (p = 0.012). The SF-36 role limitations due to emotional problems (p = 0.021), energy (fatigue) (p = 0.035), and general health (p = 0.042) domains score significantly improved after CPAP treatment for 3 months. The PSQI mean score at baseline was 12.6 ± 2.9 and in the post-treatment group, it was -5.5 ± 2.3 (p = 0.001). The ESS also changed significantly from a pretreatment mean score of 10.9 ± 5.7 to -5.3 ± 3.2 (p = 0.002) after 3 months. Conclusions: Improvement in HRQL is seen even after a short treatment period with CPAP. Questionnaires are a good tool to evaluate CPAP treatment efficacy.


Subject(s)
Quality of Life , Sleep Apnea, Obstructive , Adolescent , Adult , Aged , Air Pressure , Continuous Positive Airway Pressure , Humans , Middle Aged , Quality of Life/psychology , Sleep , Sleep Apnea, Obstructive/complications , Sleep Apnea, Obstructive/diagnosis , Sleep Apnea, Obstructive/therapy , Young Adult
2.
Medicina (Kaunas) ; 57(12)2021 Nov 29.
Article in English | MEDLINE | ID: covidwho-1592875

ABSTRACT

Diffuse pulmonary lymphangiomatosis (DPL), an exceptionally rare disease, mainly occurs in children and young adults of both sexes. Even though DPL is considered to be a benign disease, its prognosis is relatively poor. Because of its rarity, little guidance on diagnosis and treatment is available, which makes working with patients with DPL challenging for clinicians. We present here a case of a young man with DPL in whom treatment with sirolimus and propranolol rapidly achieved positive radiological and clinical effects.


Subject(s)
Lung Diseases , Lymphangiectasis , Child , Female , Humans , Male , Propranolol/therapeutic use , Sirolimus/therapeutic use , Treatment Outcome
3.
Medicina (Kaunas) ; 57(3)2021 Mar 18.
Article in English | MEDLINE | ID: covidwho-1167652

ABSTRACT

The COVID-19 pandemic dramatically changed medical care. Healthcare professionals are faced with new issues. Patients who survived COVID-19 have plenty of different continuing symptoms, of which the most common are fatigue and breathlessness. It is not well known how to care for patients with persistent or worsening respiratory symptoms and changes on chest X-ray following COVID-19 pneumonia. In this article, we talk about a subgroup of patients with organizing pneumonia following COVID-19 pneumonia that could be effectively treated with systemic glucocorticoids. It is important that patients with COVID-19 pneumonia be followed-up at least three weeks after diagnosis, in order to recognize early lung damage. We are providing a management algorithm for early diagnosis of lung diseases after COVID-19 pneumonia.


Subject(s)
COVID-19/complications , Lung Diseases, Interstitial/diagnosis , Algorithms , Biopsy , COVID-19/diagnosis , COVID-19/physiopathology , Computed Tomography Angiography , Disease Management , Early Diagnosis , Glucocorticoids/therapeutic use , Humans , Lung/diagnostic imaging , Lung/pathology , Lung/physiopathology , Lung Diseases, Interstitial/drug therapy , Lung Diseases, Interstitial/etiology , Lung Diseases, Interstitial/physiopathology , Pulmonary Diffusing Capacity , SARS-CoV-2 , Spirometry , Tomography, X-Ray Computed , Walk Test , Post-Acute COVID-19 Syndrome , COVID-19 Drug Treatment
SELECTION OF CITATIONS
SEARCH DETAIL